SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fagard Robert) "

Sökning: WFRF:(Fagard Robert)

  • Resultat 1-10 av 25
  • [1]23Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Rydén, Lars, et al. (författare)
  • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
  • 2013
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 34:39, s. 3035-3087
  • Tidskriftsartikel (refereegranskat)abstract
    • This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions. The growing awareness of the strong biological relationship between DM and CVD rightly prompted these two large organizations to collaborate to generate guidelines relevant to their joint interests, the first of which were published in 2007. Some assert that too many guidelines are being produced but, in this burgeoning field, five years in the development of both basic and clinical science is a long time and major trials have reported in this period, making it necessary to update the previous Guidelines.
  •  
7.
  • Teo, Koon K., et al. (författare)
  • Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists Collaboration
  • 2011
  • Ingår i: Journal of Hypertension. - 0263-6352 .- 1473-5598. ; 29:4, s. 623-635
  • Forskningsöversikt (refereegranskat)abstract
    • Background Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) reduce cardiovascular disease (CVD) events, but a recent meta-analysis of selected studies suggested that ARBs may increase cancer risks.Objective Candesartan, irbesartan, telmisartan, valsartan, and losartan were assessed for incident cancers in 15 large parallel long-term multicenter double-blind clinical trials of these agents involving 138 769 participants.Patients and methods Individuals at high CVD risk were randomized to telmisartan (three trials, n=51 878), irbesartan (three trials, n=14 859), valsartan (four trials, n=44 264), candesartan (four trials, n=18 566), and losartan (one trial, n=9193) and followed for 23-60 months. Incident cancer cases were compared in patients randomized to ARBs versus controls. In five trials (n=42 403), the ARBs were compared to ACEi and in 11 trials (n=63 313) to controls without ACEi. In addition, in seven trials (n=47 020), the effect of ARBs with ACEi was compared to ACEi alone and in two trials ARBs with ACEi versus ARB alone (n=25 712).Results Overall, there was no excess of cancer incidence with ARB therapy compared to controls in the 15 trials [ 4549 (6.16%) cases of 73 808 allocated to ARB versus 3856 (6.31%) of 61 106 assigned to non-ARB controls; odds ratio (OR) 1.00, 95% confidence interval (CI) 0.95-1.04] overall or when individual ARBs were examined. ORs comparing combination therapy with ARB along with ACEi versus ACEi was 1.01 (95% CI 0.94-1.10), combination versus ARB alone 1.02 (95% CI 0.91-1.13), ARB alone versus ACEi alone 1.06 (95% CI 0.97-1.16) and ARB versus placebo/control without ACEi 0.97 (95% CI 0.91-1.04). There was no excess of lung, prostate or breast cancer, or overall cancer deaths associated with ARB treatment.Conclusion There was no significant increase in the overall or site-specific cancer risk from ARBs compared to controls.
  •  
8.
  •  
9.
  • Bejan-Angoulvant, Theodora, et al. (författare)
  • Treatment of hypertension in patients 80 years and older : the lower the better? A meta-analysis of randomized controlled trials.
  • 2010
  • Ingår i: Journal of Hypertension. - 0263-6352 .- 1473-5598. ; 28:7, s. 1366-1372
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Results of randomized controlled trials are consistent in showing reduced rates of stroke, heart failure and cardiovascular events in very old patients treated with antihypertensive drugs. However, inconsistencies exist with regard to the effect of these drugs on total mortality. Methods: We performed a meta-analysis of available data on hypertensive patients 80 years and older by selecting total mortality as the main outcome. Secondary outcomes were coronary events, stroke, cardiovascular events, heart failure and cause-specific mortality. The common relative risk (RR) of active treatment versus placebo or no treatment was assessed using a random-effect model. Linear meta-regression was performed to explore the relationship between intensity of antihypertensive therapy and blood pressure (BP) reduction and the log-transformed value of total mortality odds ratios (ORs). Results: The overall RR for total mortality was 1.06 (95% confidence interval 0.89–1.25), with significant heterogeneity between hypertension in the very elderly trial (HYVET) and the other trials. This heterogeneity was not explained by differences in the follow-up duration between trials. The meta-regression suggested that a reduction in mortality was achieved in trials with the least BP reductions and the lowest intensity of therapy. Antihypertensive therapy significantly reduced (P < 0.001) the risk of stroke (35%), cardiovascular events (27%) and heart failure (50%). Cause-specific mortality was not different between treated and untreated patients. Conclusion: Treating hypertension in very old patients reduces stroke and heart failure with no effect on total mortality. The most reasonable strategy is the one associated with significant mortality reduction; thiazides as first-line drugs with a maximum of two drugs.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 25
  • [1]23Nästa
Typ av publikation
tidskriftsartikel (23)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (25)
Författare/redaktör
Fagard, Robert (25)
De Backer, Guy (13)
Cifkova, Renata (13)
Kjeldsen, Sverre E (13)
Dean, Veronica (12)
Laurent, Stephane (12)
visa fler...
Funck-Brentano, Chri ... (12)
Tendera, Michal (10)
Zamorano, Jose Luis (10)
Nilsson, Peter M (10)
Vahanian, Alec (10)
Narkiewicz, Krzyszto ... (10)
Schmieder, Roland E. (10)
Sechtem, Udo (10)
Dominiczak, Anna (10)
Reiner, Željko (9)
Viigimaa, Margus (9)
Sirnes, Per Anton (9)
Zanchetti, Alberto (9)
Redon, Josep (8)
Widimsky, Petr (7)
Kolh, Philippe (7)
Knuuti, Juhani (7)
Torbicki, Adam (7)
Windecker, Stephan (7)
Filippatos, Gerasimo ... (7)
Dickstein, Kenneth (7)
Hasdai, David (7)
Baumgartner, Helmut (7)
Kirchhof, Paulus (7)
Deaton, Christi (7)
Hoes, Arno (7)
Ponikowski, Piotr (6)
Nilsson, Peter (6)
Bax, Jeroen J (6)
Grobbee, Diederick E ... (6)
Grassi, Guido (6)
Popescu, Bogdan A (6)
Jaarsma, Tiny (5)
McDonagh, Theresa (5)
Zannad, Faiez (5)
De Caterina, Raffael ... (5)
Sleight, Peter (5)
Lindholm, Lars H (5)
Kristensen, Steen Da ... (5)
Silber, Sigmund (5)
Camm, John (5)
Ceconi, Claudio (5)
Moulin, Cyril (5)
McGregor, Keith (5)
visa färre...
Lärosäte
Lunds universitet (8)
Uppsala universitet (7)
Umeå universitet (5)
Linköpings universitet (5)
Göteborgs universitet (4)
Linnéuniversitetet (4)
visa fler...
Karolinska Institutet (1)
visa färre...
Språk
Engelska (24)
Italienska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (14)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy